$2.86
3.70% yesterday
Nasdaq, Oct 15, 10:10 pm CET
ISIN
US98420X1037
Symbol
XFOR

X4 Pharmaceuticals, Inc. Stock price

$2.86
-0.13 4.35% 1M
-3.38 54.17% 6M
-19.15 87.00% YTD
-13.84 82.88% 1Y
-57.14 95.23% 3Y
-184.94 98.48% 5Y
-2,522.54 99.89% 10Y
-2,522.54 99.89% 20Y
Nasdaq, Closing price Wed, Oct 15 2025
-0.11 3.70%
ISIN
US98420X1037
Symbol
XFOR
Industry

Key metrics

Basic
Market capitalization
$65.3m
Enterprise Value
$78.2m
Net debt
$12.9m
Cash
$63.0m
Shares outstanding
8.0m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
2.0 | 1.8
EV/Sales
2.4 | 2.2
EV/FCF
negative
P/B
16.5
Financial Health
Equity Ratio
15.1%
Return on Equity
-169.1%
ROCE
-128.7%
ROIC
-314.8%
Debt/Equity
19.1
Financials (TTM | estimate)
Revenue
$32.8m | $36.0m
EBITDA
$-104.5m | -
EBIT
$-105.9m | $-80.8m
Net Income
$-102.0m | $-30.0m
Free Cash Flow
$-112.4m
Growth (TTM | estimate)
Revenue
5,751.8% | 1,305.9%
EBITDA
15.1% | -
EBIT
14.3% | 42.8%
Net Income
-678.4% | 20.0%
Free Cash Flow
6.1%
Margin (TTM | estimate)
Gross
83.0%
EBITDA
-318.9% | -
EBIT
-323.1%
Net
-311.2% | -83.3%
Free Cash Flow
-343.0%
More
EPS
$-13.8
FCF per Share
$-14.1
Short interest
9.2%
Employees
143
Rev per Employee
$20.0k
Show more

Is X4 Pharmaceuticals, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,003 stocks worldwide.

X4 Pharmaceuticals, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

11 Analysts have issued a X4 Pharmaceuticals, Inc. forecast:

10x Buy
91%
1x Hold
9%

Analyst Opinions

11 Analysts have issued a X4 Pharmaceuticals, Inc. forecast:

Buy
91%
Hold
9%

Financial data from X4 Pharmaceuticals, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Jun '25
+/-
%
33 33
5,752% 5,752%
100%
- Direct Costs 5.57 5.57
1,963% 1,963%
17%
27 27
8,967% 8,967%
83%
- Selling and Administrative Expenses 55 55
13% 13%
169%
- Research and Development Expense 78 78
3% 3%
237%
-105 -105
15% 15%
-319%
- Depreciation and Amortization 1.37 1.37
219% 219%
4%
EBIT (Operating Income) EBIT -106 -106
14% 14%
-323%
Net Profit -102 -102
678% 678%
-311%

In millions USD.

Don't miss a Thing! We will send you all news about X4 Pharmaceuticals, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

X4 Pharmaceuticals, Inc. Stock News

Neutral
GlobeNewsWire
29 days ago
Organizational restructuring including a 50% reduction in workforce that is anticipated to result in annualized cost savings of approximately $13M John Volpone appointed Chief Operating Officer, in addition to his current role as President Dr. Adam Craig, Executive Chairman, to have oversight over clinical development BOSTON, Sept. 17, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR),...
Neutral
GlobeNewsWire
2 months ago
BOSTON, Aug. 15, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today announced that, effective on August 12, 2025, the company issued inducement awards to Adam Craig, M.D., John Volpone and David Kirske under the X4 Pharmaceuticals, Inc. 2019 Inducement Equity Incentive Plan (the “2019 Inducem...
Neutral
GlobeNewsWire
2 months ago
BOSTON, Aug. 13, 2025 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals (Nasdaq: XFOR), a company driven to improve the lives of people with rare diseases of the immune system, today closed an upsized private placement of 11,040,776 shares of common stock and pre-funded warrants to purchase 48,852,772 shares of common stock for total offering proceeds of $85 million. The originally announced offering of $...
More X4 Pharmaceuticals, Inc. News

Company Profile

X4 Pharmaceuticals, Inc. operates as a biotechnology company, which engages in developing human antibodies for treating infectious diseases. The company focuses on restoring healthy immune system function by developing novel therapeutics for the treatment of rare diseases. Its products in pipeline include X4P-001, X4P-002, and X4P-003. The company was founded by Henri A. Termeer, Keith T. Flaherty, Renato T. Skerlj, Richard Peters and Paula Ragan and is headquartered in Cambridge, MA.

Head office United States
CEO Paula Ragan
Employees 143
Founded 2010
Website www.x4pharma.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today